ZEEV NEMIROVSKY: Open Payments
NPI 1679015747 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,705 in 260 payments from 19 companies in 2025. Trend: 2023 $4,208 · 2024 $3,488 · 2025 $4,705
Food & beverage: $4,612Education: $93
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 101 | $1,571 |
| Janssen Biotech, Inc. | 25 | $539 |
| Madrigal Pharmaceuticals | 20 | $531 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $454 |
| GENZYME CORPORATION | 19 | $399 |
| PFIZER INC. | 17 | $310 |
| Aimmune Therapeutics, Inc. | 12 | $223 |
| Gilead Sciences, Inc. | 14 | $173 |
| Ardelyx, Inc. | 13 | $148 |
| Ipsen Biopharmaceuticals, Inc | 4 | $101 |
Products named: RINVOQ, TREMFYA, REZDIFFRA, CREON, DUPIXENT, ENTYVIO, SKYRIZI, VELSIPITY.
Industry payments across MD — which companies pay providers there.
